Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection Kaitlyn Bader, Senior Editor NEWS PROVIDED BY Alphyn Biologics July 14, 2023 AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component. Read the Dermatology Times article…

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection NEWS PROVIDED BY Alphyn Biologics Jul 14, 2023, 07:30 ET Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis ANNAPOLIS, Md. and ASHEVILLE,┬áN.C., July 14, 2023 /PRNewswire/ — Alphyn Biologics,…